Industries > Pharma > The Molecular Diagnostics (MDx) Market Forecast 2017-2027

The Molecular Diagnostics (MDx) Market Forecast 2017-2027

Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing

PUBLISHED: 08 August 2017
PAGES: 206
PRODUCT CODE: PHA0222

Clear
WOOCS 2.2.1

The molecular diagnostics (MDx) market was worth $6.13bn in 2016 and is estimated to grow at a CAGR of 12.5% from 2017-2021. The fastest growing segment of the molecular diagnostics market over the forecast period 2017-2027 will be the oncology testing segment. The segment was worth $1.08bn in 2016 and represented 17.6% of the molecular diagnostics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 135 charts – all unavailable elsewhere.

The 206-page report provides clear detailed insight into the molecular diagnostics (MDx) market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

World IVD market forecasts from 2017-2027

Molecular diagnostics (MDx) market forecasts from 2017-2027

The Molecular Diagnostics (MDx) Market Forecast 2017-2027

Revenue and growth forecasts to 2027 for the leading submarkets:
• Infectious Disease Testing
• Oncology Testing
• Blood Screening
• Genetic Testing
• Tissue Typing

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– Europe:
• Germany
• UK
• Spain
• Italy
• France
• Rest of Europe
– Japan
– China
– Brazil
– Russia
– India
– South Korea
– Mexico
– RoW

• This report discusses the leading companies in the molecular diagnostics (MDx) market:
• Roche Diagnostics
• Qiagen
• Hologic
• Becton, Dickinson & Company
• bioMérieux
• Agilent Technologies

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Analysis of assays and instruments currently on the market as well as pipeline products
• Acquisitions and strategic partnerships

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the molecular diagnostics (MDx) market

Visiongain’s study is intended for anyone requiring commercial analyses for the molecular diagnostics (MDx). You find data, trends and predictions.

Buy our report today The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for The Molecular Diagnostics (MDx) Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for The Molecular Diagnostics (MDx) Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category